• Je něco špatně v tomto záznamu ?

Stereotactic radiotherapy for spinal hemangioblastoma - disease control and volume analysis in long-term follow up

J. Cvek, L. Knybel, S. Reguli, R. Lipina, P. Hanzlikova, P. Šilhán, K. Resova, T. Blazek, M. Palicka, D. Feltl

. 2022 ; 27 (1) : 134-141. [pub] 20220322

Jazyk angličtina Země Polsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017545

Background: This retrospective analysis evaluated the long-term outcome of spinal stereotactic body radiotherapy (SBRT) treatment for hemangioblastomas. Materials and methods: Between 2010 and 2018, 5 patients with 18 Von-Hippel Lindau-related pial-based spinal hemangioblastomas were treated with fractionated SBRT. After precisely registering images of all relevant datasets, we delineated the gross tumor volume, spinal cord (including intramedullary cysts and/or syrinxes), and past radiotherapy regions. A sequential optimization algorithm was used for dose determinations, and patients received 25-26 Gy in five fractions or 24 Gy in three fractions. On-line image guidance, based on spinal bone structures, and two orthogonal radiographs were provided. The actuarial nidus control, surgery-free survival, cyst/syrinx changes, and progression-free survival were calculated with the Kaplan-Meier method. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Results: The median follow-up was 5 years after SBRT. Patients displayed one nidus progression, one need of neurosurgery, and two cyst/syrinx progressions directly connected to symptom worsening. No SBRT-related complications or acute adverse radiation-related events occurred. However, one asymptomatic radiological sign of myelopathy occurred two years after SBRT. All tumors regressed; the one-year equivalent tumor volume reduction was 0.2 mL and the median volume significantly decreased by 28% (p = 0.012). Tumor volume reductions were not correlated with the mean (p = 0.19) or maximum (p = 0.16) dose. Conclusions: SBRT for pial-based spinal hemangioblastomas was an effective, safe, viable alternative to neurosurgery in asymptomatic patients. Escalating doses above the conventional dose-volume limits of spinal cord tolerance showed no additional benefit.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017545
003      
CZ-PrNML
005      
20220720100255.0
007      
ta
008      
220718s2022 pl f 000 0|eng||
009      
AR
024    7_
$a 10.5603/RPOR.a2022.0003 $2 doi
035    __
$a (PubMed)35402025
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Cvek, Jakub $u Department of Oncology, Faculty of Medicine and University Hospital Ostrava, Ostrava, Czech Republic
245    10
$a Stereotactic radiotherapy for spinal hemangioblastoma - disease control and volume analysis in long-term follow up / $c J. Cvek, L. Knybel, S. Reguli, R. Lipina, P. Hanzlikova, P. Šilhán, K. Resova, T. Blazek, M. Palicka, D. Feltl
520    9_
$a Background: This retrospective analysis evaluated the long-term outcome of spinal stereotactic body radiotherapy (SBRT) treatment for hemangioblastomas. Materials and methods: Between 2010 and 2018, 5 patients with 18 Von-Hippel Lindau-related pial-based spinal hemangioblastomas were treated with fractionated SBRT. After precisely registering images of all relevant datasets, we delineated the gross tumor volume, spinal cord (including intramedullary cysts and/or syrinxes), and past radiotherapy regions. A sequential optimization algorithm was used for dose determinations, and patients received 25-26 Gy in five fractions or 24 Gy in three fractions. On-line image guidance, based on spinal bone structures, and two orthogonal radiographs were provided. The actuarial nidus control, surgery-free survival, cyst/syrinx changes, and progression-free survival were calculated with the Kaplan-Meier method. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Results: The median follow-up was 5 years after SBRT. Patients displayed one nidus progression, one need of neurosurgery, and two cyst/syrinx progressions directly connected to symptom worsening. No SBRT-related complications or acute adverse radiation-related events occurred. However, one asymptomatic radiological sign of myelopathy occurred two years after SBRT. All tumors regressed; the one-year equivalent tumor volume reduction was 0.2 mL and the median volume significantly decreased by 28% (p = 0.012). Tumor volume reductions were not correlated with the mean (p = 0.19) or maximum (p = 0.16) dose. Conclusions: SBRT for pial-based spinal hemangioblastomas was an effective, safe, viable alternative to neurosurgery in asymptomatic patients. Escalating doses above the conventional dose-volume limits of spinal cord tolerance showed no additional benefit.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Knybel, Lukas $u Department of Oncology, Faculty of Medicine and University Hospital Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000224616606
700    1_
$a Reguli, Stefan $u Department of Neurosurgery, Faculty of Medicine and University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Lipina, Radim $u Department of Neurosurgery, Faculty of Medicine and University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Hanzlikova, Pavla $u Department of Radiology, Faculty of Medicine and University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Šilhán, Petr $u Department of Psychiatry, Faculty of Medicine and University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Resova, Kamila $u Department of Oncology, Faculty of Medicine and University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Blazek, Tomas $u Department of Oncology, Faculty of Medicine and University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Palicka, Martin $u Department of Oncology, Faculty of Medicine and University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Feltl, David $u Department of Oncology, General University Hospital in Prague, Prague, Czech Republic
773    0_
$w MED00154188 $t Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology $x 1507-1367 $g Roč. 27, č. 1 (2022), s. 134-141
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35402025 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100250 $b ABA008
999    __
$a ind $b bmc $g 1816641 $s 1168787
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 27 $c 1 $d 134-141 $e 20220322 $i 1507-1367 $m Reports of Practical Oncology and Radiotherapy $n Rep Pract Oncol Radiother $x MED00154188
LZP    __
$a Pubmed-20220718

Najít záznam

Citační ukazatele

Možnosti archivace